CMP Pharma announces calcium channel blocker ‘Norliqva’ availability

Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.

Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS

Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022

Ovensa and Celanese to collaborate to advance precision drug delivery

Vial to launch oncology CRO, Arati Rao named as First Advisor

The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.

BGS Gleneagles launches its refurbished advanced emergency & trauma center

120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care

Cipla adds capacity of captive renewable energy power plant in Maharashtra & Karnataka

By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.

FDA approves Roche’s Evrysdi for use in babies under two months with SMA

Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date

ENTOD Pharmaceuticals gets DCGI nod to carry out the phase 3 trials of 0.05% atropine eye drops

Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children

Ayu Health Hospitals announces t expansion plan in Rajasthan

This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.

USFDA accepts dupilumab for priority review in adults with prurigo nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved